5-Fluoro-DET
![]() | |
Clinical data | |
---|---|
Other names |
|
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C14H19FN2 |
Molar mass | 234.318 g·mol−1 |
3D model (JSmol) | |
| |
|
5-Fluoro-DET (5F-DET, 5-fluoro-N,N-diethyltryptamine) is a tryptamine derivative related to drugs such as DET and 5-MeO-DET.[1][2] It acts as an inhibitor of the enzyme myeloperoxidase,[3] and is also thought to be an agonist at the 5-HT2A receptor.[4]
See also
[edit]References
[edit]- ^ Pelchowicz Z, Kaluszyner A, Bentov M (1961). "1067. N-alkylated 5-fluorotryptamines". Journal of the Chemical Society (Resumed): 5418–5421. doi:10.1039/JR9610005418.
- ^ Kalir A, Szara S (May 1966). "Synthesis and pharmacological activity of alkylated tryptamines". Journal of Medicinal Chemistry. 9 (3): 341–4. doi:10.1021/jm00321a017. PMID 5960901.
- ^ Soubhye J, Prévost M, Van Antwerpen P, Zouaoui Boudjeltia K, Rousseau A, Furtmüller PG, Obinger C, Vanhaeverbeek M, Ducobu J, Néve J, Gelbcke M, Dufrasne FO (December 2010). "Structure-based design, synthesis, and pharmacological evaluation of 3-(aminoalkyl)-5-fluoroindoles as myeloperoxidase inhibitors" (PDF). Journal of Medicinal Chemistry. 53 (24): 8747–59. doi:10.1021/jm1009988. PMID 21090682. S2CID 207225972.
- ^ WO 2021/168082, Kruegel AC, Sporn J, "Specific Tryptamines for use in the Treatment of Mood Disorders.", published 26 August 2021, assigned to Gilgamesh Pharmaceuticals, Inc..